2025 Insurance Coverage and Processing Labelling 
Putting Patients First Blog
JANUARY 27, 2025
Coverage of Anti-Obesity Medications (AOMs) The NHC applauds CMS for aligning with the medical community and proposing to recognize obesity as a chronic disease and allow Medicare Part D coverage for AOMs. Below, we provide detailed comments and recommendations on key provisions of the proposed rule.
Big Molecule Watch
AUGUST 25, 2023
Congress left Medicare drug pricing to the drug manufacturers, pharmacies, and insurance plan sponsors to determine, and expressly prohibited the government from “interfering” in those private price negotiations under the so-called “Non-Interference Clause” of the Medicare Modernization Act of 2003.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 16, 2025
Robert Barrie June 16, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Elevidys is the only gene therapy approved in US for DMD. By GlobalData Learn more about Strategic Intelligence Corwin added that Elevidys’s label will likely be updated to reflect the risk of ALF. Dragon Claws via Shutterstock.
Pharmaceutical Technology
JUNE 13, 2025
Robert Barrie June 13, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink.
Pharmacy Times
JUNE 16, 2025
The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. Second, it does not address the core issues of higher prices, such as the use of rebates by insurers. May 12, 2025.
Expert insights. Personalized for you.
40 
Let's personalize your content